Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cutaneous Pleomorphic Sarcoma Prognosis Examined

J Am Acad Dermatol; ePub 2018 Nov 8; Ibanez, et al

Tumor size, grade, gender, age at diagnosis, and race appear to influence survival as prognostic factors in cutaneous pleomorphic sarcoma (CPS), according to a recent study. Furthermore, surgical tumor extirpation provides a survival benefit over no treatment whereas primary or adjuvant radiation does not provide a survival benefit. National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data (1972-2013) were analyzed for 2,423 patients diagnosed with CPS. Researchers found:

  • Age-adjusted incidence rate was 0.152 cases per 100,000 person-years and was 4.5-fold higher in males than females.
  • Male gender, white race, and increasing age >40 years were significantly associated with decreased overall survival.
  • Head and neck tumors, tumors >15mm, and with grade III or IV histology had significantly decreased survival.
  • Surgical excision had a survival benefit compared to no treatment.
  • Radiation therapy did not provide a survival benefit.
  • Patients with localized disease had the greatest survival followed by regional and distant disease.
Citation:

Ibanez, MA, Rismiller K, Knackstedt T. Prognostic factors, treatment, and survival in cutaneous pleomorphic sarcoma. [Published online ahead of print November 8, 2018]. J Am Acad Dermatol. doi:10.1016/j.jaad.2018.08.054.